Navigation Links
Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/12/2009

and classified as long-term investments. Total liabilities, excluding deferred revenue of $16.0 million, were $8.5 million at December 31, 2008.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. NTI has an early-stage development program for Alzheimer's disease and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials and our continuing contractual commitments, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.




                         CONDENSED STATEMENTS OF OPERATIONS
               (Unaudited - in thousands, except per share amounts)


                                    Three months ended   Six months ended
                                        December 31,        Decem
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Suspension of Viprinex Development
3. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
4. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
5. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
6. Neurobiological Technologies Sets Date for First Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
8. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
9. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
11. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
(Date:7/10/2014)... research may help in the fight against terrorism with ... quantities of explosives with the use of light and ... Sensors and Actuators B: Chemical , the researchers describe ... in concentrations as low as 6.3 ppm (parts per ... few minutes. , "Traditionally explosives detection has involved looking ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2
... Submission demonstrates progress of plant-derived insulin program, ... -, TSX symbol: SBS, CALGARY, July ... company developing a portfolio of therapeutic,proteins for metabolic ... an Investigational New Drug (IND) application for,safflower-produced recombinant ...
... ArunA Biomedical, Inc., the first,company to commercialize human ... that William T. Sharp has been named President,and ... leadership,responsibilities, Mr. Sharp has also been appointed to ... Steven Stice, PhD, who will,remain ArunA,s Chairman and ...
... MADISON Though bacteria are everywhere from the air we ... the vast majority are innocuous or even beneficial, and only ... microbial guest from an unwanted intruder? , Research from the ... but with the host. , A study appearing online this week ...
Cached Biology Technology:SemBioSys submits IND for safflower-produced insulin to U.S. FDA 2SemBioSys submits IND for safflower-produced insulin to U.S. FDA 3ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2Symbiotic microbes induce profound genetic changes in their hosts 2
(Date:7/11/2014)... City of Entiat on Tuesday, July 8, 2014. Despite ... to over 1,000 acres by evening. Three outbuildings were ... by the Washington Department of Natural Resources. The ... developing fire control strategies and tactics. Other cooperators include ... Natural Resources, (WA DNR), Bureau of Land Management, Chelan ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... IODP Arctic Coring Expedition (ACEX) is making news with new ... Nature, an article by several of the expedition scientists summarizes ... unusually wet, and ice-free up to the time the last ... atmosphere ?a period calculated to have occurred 55 million years ...
... designated Special Areas of Conservation throughout the UK, including ... pile driving. The frequency range of pile driving noise ... and avoid predators. This has the potential to affect ... Lactating females and young calves might be particularly vulnerable ...
... studies offer new evidence suggesting an alternative form of natural ... the blood in humans at levels determined to protect against ... in eight different forms. The primary vitamin E on drugstore ... of vitamin E surfacing as a potent neuroprotective agent in ...
Cached Biology News:Arctic coring expedition continues to yield new clues 2Dolphins at risk 2Natural vitamin E tocotrienol reaches blood at protective levels 2Natural vitamin E tocotrienol reaches blood at protective levels 3
...
... MMPs are a group of enzymes involved ... of matrix metalloproteinase family ten exist in ... membrane proteins. MT1-MMP, MT2-MMP, MT3-MMP also known ... C-terminal transmembrane domain anchoring them to the ...
...
... TURRAX Tube Disperser System from IKA Works is ... a cleaner, safer, and more efficient way to ... from 2 to 15 ml inside sealed tubes. ... one of 4 different tube types. Each tube ...
Biology Products: